title: Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
authors.affiliation: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
authors.forename: Marc B
authors.initials: MB
authors.lastname: Garnick
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011804:Quinolines; C553176:tivozanib; D009536:Niacinamide; D000077157:Sorafenib